| Recruiting | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers Healthy Volunteers | Phase 1 | 2026-03-02 |
| Recruiting | A Study to Evaluate ALN-2232 in Participants With Obesity Obesity | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN | Phase 3 | 2026-01-16 |
| Recruiting | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus (T2DM) | Phase 2 | 2026-01-15 |
| Recruiting | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World S Transthyretin Amyloidosis With Cardiomyopathy | — | 2026-01-09 |
| Recruiting | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers Healthy Volunteers | Phase 1 | 2025-12-12 |
| Recruiting | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease Alzheimer's Disease | Phase 1 | 2025-10-15 |
| Recruiting | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk | Phase 3 | 2025-09-22 |
| Recruiting | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | 2025-07-02 |
| Recruiting | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients Wit Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | 2025-03-03 |
| Recruiting | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | 2024-12-30 |
| Enrolling By Invitation | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | 2024-12-03 |
| Recruiting | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HH Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | 2024-11-07 |
| Completed | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers Healthy Volunteers | Phase 1 | 2024-11-05 |
| Recruiting | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease Huntington's Disease | Phase 1 | 2024-10-14 |
| Completed | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension Mild to Moderate Hypertension | Phase 1 / Phase 2 | 2024-06-05 |
| Recruiting | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy Cerebral Amyloid Angiopathy | Phase 2 | 2024-05-17 |
| Recruiting | Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthy Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic Carrier State | — | 2024-04-25 |
| Completed | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Contro High Cardiovascular Risk, Hypertension | Phase 2 | 2024-02-29 |
| Terminated | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | 2023-03-10 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Transthyretin-Mediated Amyloidosis | Phase 1 | 2023-01-16 |
| Terminated | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout Gout | Phase 1 / Phase 2 | 2022-02-25 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD Early-Onset Alzheimer Disease | Phase 1 | 2022-02-04 |
| Terminated | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urina Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels | Phase 2 | 2022-01-27 |
| Active Not Recruiting | BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) Primary Hyperoxaluria Type 1 | — | 2021-12-13 |
| Completed | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care An Hypertension | Phase 2 | 2021-11-05 |
| Completed | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension Hypertension | Phase 2 | 2021-07-07 |
| Recruiting | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) Acute Hepatic Porphyria | — | 2021-04-26 |
| Recruiting | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyl Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis | — | 2020-11-23 |
| Terminated | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Nonalcoholic Steatohepatitis, NASH | Phase 1 | 2020-10-09 |
| Recruiting | Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy | — | 2020-08-01 |
| Completed | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1, Primary Hyperoxaluria | Phase 3 | 2020-01-21 |
| Completed | A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy o Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy | — | 2019-12-18 |
| Active Not Recruiting | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | 2019-11-26 |
| Terminated | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA | Phase 2 | 2019-09-30 |
| Active Not Recruiting | APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (AT Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | 2019-09-12 |
| Completed | A Study to Evaluate ALN-AGT01 in Patients With Hypertension Hypertension | Phase 1 | 2019-05-01 |
| Completed | A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1) | Phase 3 | 2019-04-22 |
| Completed | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progressi Amyloidosis, Familial, Transthyretin Amyloidosis | Phase 3 | 2019-03-27 |
| Completed | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amy Amyloidosis, Hereditary, Transthyretin Amyloidosis | Phase 3 | 2019-02-14 |
| Terminated | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease Amyloidosis, Leukocyte Chemotactic Factor 2 Amyloidosis | — | 2019-01-29 |
| Terminated | A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Live ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | Phase 1 / Phase 2 | 2018-12-05 |
| Completed | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) | Phase 3 | 2018-11-27 |
| Terminated | INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Acute Hepatic Porphyria, Hepatic Porphyrias, Acute Intermittent Porphyria (AIP) | — | 2018-05-29 |
| Completed | A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute In Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent | Phase 1 | 2018-04-26 |
| Completed | An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria PH1, Primary Hyperoxaluria, RNAi Therapeutic | Phase 2 | 2018-04-04 |
| Completed | ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Po Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent | Phase 3 | 2017-11-16 |
| Withdrawn | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Atypical Hemolytic Uremic Syndrome | Phase 2 | 2017-09-19 |
| Completed | A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Interm Acute Intermittent Porphyria | Phase 1 / Phase 2 | 2016-10-01 |
| Terminated | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic | Phase 1 | 2016-06-24 |
| Completed | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | Phase 1 | 2016-06-07 |
| Completed | Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) | Phase 1 / Phase 2 | 2016-03-08 |
| Completed | The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP), ATTR Amyloidosis | Phase 2 | 2015-10-01 |
| Completed | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis | Phase 3 | 2015-07-16 |
| Terminated | A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antit Antitrypsin Deficiency Liver Disease | Phase 1 | 2015-07-09 |
| Completed | A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) Acute Intermittent Porphyria | Phase 1 | 2015-05-06 |
| Completed | A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 / Phase 2 | 2015-01-01 |
| Completed | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Fa Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial | Phase 3 | 2014-12-01 |
| Completed | A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Chole Hypercholesterolemia | Phase 1 | 2014-12-01 |
| Completed | A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis TTR-mediated Amyloidosis | Phase 2 | 2014-10-01 |
| Completed | EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP) Acute Hepatic Porphyria | — | 2014-08-01 |
| Completed | DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidos Familial Amyloidotic Cardiomyopathy (FAC) | — | 2014-06-01 |
| Completed | A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers Transthyretin (TTR)-Mediated Amyloidosis | Phase 1 | 2014-01-01 |
| Completed | Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis TTR-mediated Amyloidosis | Phase 2 | 2013-12-01 |
| Completed | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial | Phase 3 | 2013-11-01 |
| Completed | The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients W TTR-mediated Amyloidosis | Phase 2 | 2013-10-01 |
| Completed | A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic TTR-mediated Amyloidosis | Phase 1 | 2013-03-01 |
| Completed | Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis TTR-mediated Amyloidosis | Phase 2 | 2012-05-01 |
| Completed | Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects TTR-mediated Amyloidosis | Phase 1 | 2012-03-01 |
| Completed | Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) Elevated LDL-Cholesterol (LDL-C) | Phase 1 | 2011-09-01 |
| Completed | Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Trea Solid Tumors | Phase 1 | 2010-07-01 |
| Completed | Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis Transthyretin Mediated Amyloidosis (ATTR) | Phase 1 | 2010-06-01 |
| Completed | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Respiratory Syncytial Virus Infections | Phase 2 | 2010-02-01 |
| Completed | Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intraveno Solid Tumors | Phase 1 | 2009-03-01 |
| Completed | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Respiratory Syncytial Virus Infections | Phase 2 | 2008-04-01 |
| Completed | Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Vir Respiratory Syncytial Virus Infections | Phase 2 | 2007-07-01 |
| Approved For Marketing | Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial | — | — |
| No Longer Available | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiom Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy | — | — |
| Approved For Marketing | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria Acute Hepatic Porphyria | — | — |
| Approved For Marketing | Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1 Primary Hyperoxaluria | — | — |